Hsu Wesley, Lesniak Maciej S, Tyler Betty, Brem Henry
Departments of Neurosurgery and Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Neurooncol. 2005 Sep;74(2):135-40. doi: 10.1007/s11060-004-6597-8.
Local delivery of adriamycin (ADR) via biodegradable polymers has been shown to improve survival in rats challenged intracranially with 9L gliosarcoma. Likewise, local delivery of interleukin-2 (IL-2) has been shown to extend survival in experimental brain tumor models. In the current study, we hypothesized that local delivery of ADR and IL-2 might act synergistically against experimental intracranial glioma.
Polyanhydride polymers (PCPP-SA) containing 5% ADR by weight were prepared using the mix-melt method. IL-2 polymer microspheres (IL-2 MS) were produced via the complex coacervation of gelatin and chondroitin sulfate in the presence of IL-2. Sixty male Fisher 344 rats received an intracranial challenge with a lethal dose of 9L gliosarcoma cells. In addition, a group of rats were injected with either IL-2 MS or empty microspheres. Five days later they received ADR or blank polymer. There were a total of four treatment groups: (1) empty microspheres, blank polymer; (2) empty microspheres, ADR polymer; (3) IL-2 MS, blank polymer; and (4) IL-2 MS, ADR polymer.
Compared to control animals treated with empty microspheres and blank polymer, animals receiving empty microspheres and ADR polymer (P < 0.0004), IL-2 MS and blank polymer (P < 0.0005), and IL-2 MS combined with ADR polymer (P < 0.0000002) all showed statistically significant improvement in survival. In addition, animals receiving the IL-2/ADR combination had significantly extended survival compared to either ADR or IL-2 alone (P < 0.000003 and P < 0.0004, respectively).
Both ADR and IL-2, when delivered locally, are effective monotherapeutic agents against experimental intracranial gliosarcoma. The combination ADR and IL-2 therapy is more effective than either agent alone.
通过可生物降解聚合物局部递送阿霉素(ADR)已被证明可提高经9L胶质肉瘤颅内攻击的大鼠的存活率。同样,局部递送白细胞介素-2(IL-2)已被证明可延长实验性脑肿瘤模型的存活时间。在本研究中,我们假设局部递送ADR和IL-2可能对实验性颅内胶质瘤具有协同作用。
采用混合熔融法制备含5%重量ADR的聚酸酐聚合物(PCPP-SA)。IL-2聚合物微球(IL-2 MS)通过在IL-2存在下明胶和硫酸软骨素的复合凝聚法制备。60只雄性Fisher 344大鼠接受致死剂量的9L胶质肉瘤细胞颅内攻击。此外,一组大鼠注射IL-2 MS或空微球。5天后,它们接受ADR或空白聚合物。共有四个治疗组:(1)空微球、空白聚合物;(2)空微球、ADR聚合物;(3)IL-2 MS、空白聚合物;(4)IL-2 MS、ADR聚合物。
与接受空微球和空白聚合物治疗的对照动物相比,接受空微球和ADR聚合物(P < 0.0004)、IL-2 MS和空白聚合物(P < 0.0005)以及IL-2 MS与ADR聚合物联合治疗(P < 0.0000002)的动物在存活率方面均显示出统计学上的显著改善。此外,接受IL-2/ADR联合治疗的动物与单独接受ADR或IL-2治疗的动物相比,存活时间显著延长(分别为P < 0.000003和P < 0.0004)。
ADR和IL-2局部递送时,均是治疗实验性颅内胶质肉瘤的有效单一治疗药物。ADR与IL-2联合治疗比单独使用任何一种药物更有效。